Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

580
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
580
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

1.5K
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
1.5K
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

1.1K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical profile, survival, and prognostic determinants in malignant cardiac tamponade requiring pericardiocentesis.

Kardiologia polska·2026
Same author

Divergence in postoperative platelet aggregation during antiplatelet monotherapy with aspirin in the early postoperative period following coronary artery bypass grafting: initial findings.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology·2026
Same author

COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025.

MMWR. Morbidity and mortality weekly report·2026
Same author

The impact of anxiety experienced by patients undergoing surgical aortic valve replacement on perceived pain, self-efficacy, and body esteem in the perioperative period.

Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery·2026
Same author

Transcarotid transcatheter aortic valve implantation in selected patients. Authors' reply.

Kardiologia polska·2026
Same author

The triple a challenge: Staged hybrid repair of multilevel aortic aneurysms and celiac trunk occlusion in a 73-year-old woman.

Kardiologia polska·2025

Related Experiment Video

Updated: Apr 21, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.7K

Aortic valve replacement with a novel anti-calcification technology platform.

Jerzy Sadowski, Krzysztof Bartuś1, Bogusław Kapelak

  • 1Department of Cardiovascular Surgery and Transplantation, Jagiellonian University, John Paul II Hospital, Krakow, Poland. krzysztofbartus@gmail.com.

Kardiologia Polska
|November 6, 2014
PubMed
Summary

A new anti-calcification technology for bioprosthetic valves shows promising results, preventing structural valve deterioration and improving valve function in patients with aortic stenosis over one year.

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

3.8K
Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.0K

Related Experiment Videos

Last Updated: Apr 21, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.7K
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

3.8K
Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.0K

Area of Science:

  • Cardiovascular Surgery
  • Biomaterials Science
  • Medical Device Technology

Background:

  • Structural valve deterioration (SVD) due to tissue calcification is a primary cause of bioprosthetic valve failure.
  • A novel anti-calcification technology aims to irreversibly block calcium binding sites in bioprosthetic valves.

Purpose of the Study:

  • To evaluate the safety and efficacy of a novel anti-calcification technology in bioprosthetic aortic valves.
  • To assess valve performance and complication rates in patients undergoing aortic valve replacement.

Main Methods:

  • Twenty patients with severe aortic stenosis received bioprosthetic aortic valves treated with the novel technology.
  • Patients were followed for up to one year, with assessments including echocardiography for hemodynamic performance and recording of all complications.

Main Results:

  • One early death occurred; no other complications were noted up to discharge.
  • At one year, there was no valve-related mortality, SVD, major paravalvular leak, thromboembolic events, major bleeding, endocarditis, or reoperation.
  • Mean effective orifice area increased, and mean gradient decreased significantly, indicating improved valve hemodynamics.

Conclusions:

  • Early clinical experience demonstrates excellent performance, durability, and safety of bioprosthetic aortic valves treated with the novel anti-calcification technology.
  • No valve-related complications were observed in the first year post-implantation.
  • Longer-term follow-up is necessary to confirm these favorable outcomes.